Diag-Nose.io
Diag-Nose.io is an Australian biotech developing AI-powered precision respiratory diagnostics through its patented ABEL Microsampler nasal biopsy device and RhinoMAP biomarker analytics platform, serving clinicians, researchers, biobanks and biotech companies with planned clinical launch in 2027.
- Company typePrivate
- Founded2020
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Diag-Nose.io does
Diag-Nose.io is an Australian biotechnology company founded in 2020 in Melbourne that develops precision diagnostics for chronic respiratory diseases using nasal fluid biomarkers. The company's core technology stack centres on the "unified airway" concept — leveraging biological relationships between nasal passages and lungs — through two integrated offerings: the ABEL Microsampler, a patented, FDA-listed Class I nasal liquid biopsy device for standardised, omics-grade nasal fluid collection; and RhinoMAP, an AI-powered biomarker analytics platform that combines proteomics and machine learning to predict disease progression, monitor biologic treatment response and differentiate between overlapping respiratory conditions. A proprietary NEBULA database aggregates biomarker datasets to support therapeutic target identification for pharmaceutical partners. Clinical evidence is being built across 12 studies with 100+ patients recruited across Australia and the United States.
The company operates a research-tools-plus-future-clinical-software business model. Near-term revenue comes from hardware sales of the ABEL Microsampler to academic researchers, biobanks and biotech companies via an exclusive Australian distribution partnership with GO LAB Pty Ltd and direct sales in the US post-FDA listing. Forward revenue streams are planned from RhinoMAP subscriptions or licensing as a clinical decision support system (targeted clinical launch 2027, full launch 2028), companion diagnostic licensing to pharma, and data monetisation via the NEBULA database. The company is venture-backed, having raised approximately A$6.7M cumulatively across pre-seed, seed and non-dilutive grant funding, with a board including biotech operators from Sienna, Panbio and Quest Laboratories. Customers and partners include Specialty Physician Associates, Monash Health, Monash University, Mater Research, University of Florida, ENT Clinic Melbourne, Manse Medical and Invetech, anchored primarily in clinical research rather than scaled commercial volume.
Diag-Nose.io firmographics
Firmographics- Name
- Diag-Nose.io
- Legal name
- Diag-Nose.io
- Website
- https://diag-nose.io
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Diag-Nose.io is an Australian biotech developing AI-powered precision respiratory diagnostics through its patented ABEL Microsampler nasal biopsy device and RhinoMAP biomarker analytics platform, serving clinicians, researchers, biobanks and biotech companies with planned clinical launch in 2027.
- Ownership category
- akta.pro rank
Diag-Nose.io industry classification
Industry- Product category
- Precision Respiratory Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Rhinology & Sinus Surgery (HLAKAMAD), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
Keywords
Where Diag-Nose.io is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Diag-Nose.io business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- ABEL Microsampler Sales: Sale of the ABEL Microsampler nasal liquid biopsy device, a patented Class I medical device listed with FDA and registered on ARTG. Sold to researchers, clinicians, biobanks and biotech companies for nasal fluid sampling in research and diagnostic applications. Distributed through GO LAB Pty Ltd in Australia.
- RhinoMAP Diagnostic Platform (Future): AI-powered biomarker analytics platform for clinical diagnostics. Planned commercial launch as a clinical decision support system for respiratory specialists, otolaryngologists, and allergists. Expected pilot access in 2025/26 (research) and 2027 (clinical), with full commercial launch in 2028.
- Biomarker Data / Research Services: Research services supporting clinical studies and biomarker analysis for pharma/biotech companies. The company collaborates with clinical sites and research organisations to generate and analyse nasal biomarker data. Nebula database intended to support biotech companies and pharmaceutical firms with drug discovery.
- Licensing of Diagnostic Algorithms: The company has filed patent applications for diagnostic algorithms developed through clinical trials. Licensing of these algorithms to biotech companies and pharmaceutical firms for companion diagnostics and personalised treatment matching represents a future revenue opportunity.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Diag-Nose.io product offering
Product offeringCore offering
Diag-Nose.io develops and sells the ABEL Microsampler, a patented nasal liquid biopsy medical device for precise, omics-grade nasal fluid collection. The company is building the RhinoMAP AI-powered biomarker analytics platform that combines nasal microsampling with proteomics and machine learning to decode airway biology, predict treatment response, and differentiate respiratory diseases. The company also operates the NEBULA database integrating biomarker datasets for therapeutic target discovery.
Product overview
Diag-Nose.io is a biotechnology company developing a portfolio of precision respiratory diagnostic products. The product ecosystem consists of three integrated offerings: (1) ABEL Microsampler, a patented nasal liquid biopsy device for precise nasal fluid collection; (2) RhinoMAP, an AI-powered biomarker analytics platform that analyzes nasal samples using proteomics and machine learning to decode airway biology and support treatment decisions; and (3) NEBULA, a respiratory disease database integrating biomarker datasets for drug discovery. Together, these products form an end-to-end pipeline from sample collection (ABEL) through AI-powered analysis (RhinoMAP) to data infrastructure (NEBULA) for precision respiratory medicine.
Differentiator
Problem solved
Functional benefit
Brands
- ABEL Microsampler: A patented first-of-its-kind nasal liquid biopsy device with an absorptive probe designed for precise, minimally-invasive, omics-grade nasal fluid collection. Listed with the U.S. FDA and registered on the ARTG as a Class I medical device.
- RhinoMAP
- NEBULA
Products and services
- RhinoMAP AI-powered precision diagnostics platform that combines nasal microsampling, proteomics, and machine learning to decode airway biology. Predicts disease progression, monitors treatment response, and helps clinicians match patients to appropriate therapies including anti-Th2 biologics by mapping biological subtypes (endotypes).
- ABEL Microsampler Patented nasal liquid biopsy device featuring an absorptive probe for precise, minimally-invasive, omics-grade nasal fluid collection. Designed for use in respiratory disease research, neurodegenerative disorders, oncology, and occupational health applications. Listed as Class I Medical Device with the FDA and registered on the ARTG.
- NEBULA Database State-of-the-art respiratory disease database that integrates vast datasets from biomarker studies to provide insights into molecular mechanisms of respiratory conditions. Aims to identify novel therapeutic targets and optimize drug candidate selection.
- Biomarker Research Services Research services supporting clinical studies and biomarker analysis for pharma/biotech companies. Collaborates with clinical sites and research organisations to generate and analyse nasal biomarker data, supported by the NEBULA database infrastructure.
Quantifiable outcome
- Traditional diagnostic methods result in treatment failure for >30% of chronic respiratory disease patients, costing hundreds of millions of dollars per year
- +4 more outcomes
Companies that use Diag-Nose.io
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Diag-Nose.io technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Diag-Nose.io partnerships and signals
Strategic signalScale indicators13 records
Recent moves7 records
Expansion highlights7 records
Diag-Nose.io competitors and assessment
Company assessmentDirect peers
- Owlstone Medical: Develops non-invasive Breath Biopsy diagnostics for respiratory and other diseases, using exhaled biomarkers and analytics. Directly comparable in pursuing non-invasive airway biomarker diagnostics and pharma biomarker services.
- ProAxsis: UK company measuring active protease biomarkers (e.g., neutrophil elastase) for respiratory disease monitoring. Directly overlaps on respiratory biomarker measurement to guide and monitor treatment.
Emerging players
- Rhinostics: Makes automated nasal sample-collection devices for diagnostics and research. Overlaps closely with the ABEL Microsampler in standardized nasal specimen collection hardware.
- PulmoBioMed: Develops devices to capture respiratory/exhaled samples for biomarker analysis. Overlaps on non-invasive airway sample collection for downstream biomarker diagnostics.
Broad incumbents
- Circassia (Niox): Provides FeNO airway inflammation testing (NIOX) used to guide asthma and biologic treatment decisions. Comparable as a commercialized respiratory-inflammation diagnostic targeting the same specialists.
Regional players
- ResApp Health: Australian digital respiratory diagnostics company using algorithms to assess respiratory conditions. Comparable Australian respiratory-diagnostics innovator, though based on acoustic/sound analysis rather than biomarkers.
Others
- Olink Proteomics: Provides high-throughput proteomics platforms for protein biomarker discovery. An enabling/adjacent player whose technology overlaps with Diag-Nose.io's proteomics-based biomarker analytics.
- SomaLogic: Proteomics platform company measuring thousands of proteins for biomarker discovery and diagnostics. Adjacent proteomics enabler relevant to the company's protein-biomarker approach.
- Seer: Proteomics technology company enabling large-scale protein biomarker analysis. Thematically related as proteomics infrastructure supporting biomarker-driven diagnostics and drug discovery.
- DNA Genotek (OraSure): Manufactures biological sample-collection devices for research and diagnostics. Adjacent player in standardized specimen collection, comparable to the ABEL Microsampler device business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Diag-Nose.io social profiles
Digital presenceDiag-Nose.io compliance and trust
Trust signalCompliance4 records
Diag-Nose.io financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diag-Nose.io leadership team
Management profileNumber of profiles
Profiles13 records
Diag-Nose.io funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diag-Nose.io M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diag-Nose.io
What does Diag-Nose.io do?
Diag-Nose.io develops and sells the ABEL Microsampler, a patented nasal liquid biopsy medical device for precise, omics-grade nasal fluid collection. The company is building the RhinoMAP AI-powered biomarker analytics platform that combines nasal microsampling with proteomics and machine learning to decode airway biology, predict treatment response, and differentiate respiratory diseases. The company also operates the NEBULA database integrating biomarker datasets for therapeutic target discovery.
Is Diag-Nose.io a public or private company?
Diag-Nose.io is a private company. It is classified as venture growth investor backed and is currently operating.
When was Diag-Nose.io founded?
Diag-Nose.io was founded in 2020. It employs 11 to 50 people.
Where is Diag-Nose.io based?
Diag-Nose.io is headquartered in Melbourne, Australia, in the Oceania region.
How does Diag-Nose.io make money?
Four revenue lines are on record. ABEL Microsampler Sales are the primary driver. The others are rhinoMAP Diagnostic Platform (Future), biomarker Data / Research Services and licensing of Diagnostic Algorithms.
Who are Diag-Nose.io's main competitors?
Direct peers on record are Owlstone Medical and ProAxsis. Emerging players are Rhinostics and PulmoBioMed. Circassia (Niox) is listed as a broad incumbent. ResApp Health is listed as a regional player. Others are Olink Proteomics, SomaLogic, Seer and DNA Genotek (OraSure).
Does Diag-Nose.io have an API?
No public API is recorded for Diag-Nose.io.
What industry is Diag-Nose.io in?
Diag-Nose.io's product category is Precision Respiratory Diagnostics. Its primary akta.pro industry code is HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 541714 and its SIC code is 8071.